Central Nervous System Lymphoma Clinical Trials

14 recruiting

Frequently Asked Questions

Common questions about Central Nervous System Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 49 trials

Recruiting
Phase 1

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Secondary Central Nervous System LymphomaPrimary Central Nervous System (CNS) Lymphoma
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT07137494
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Primary Central Nervous System Lymphoma
National Cancer Institute (NCI)93 enrolled1 locationNCT02203526
Recruiting
Phase 3

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co. Ltd132 enrolled4 locationsNCT07104032
Recruiting
Phase 2

A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)

Primary Central Nervous System LymphomaPCNSL
Tongji Hospital110 enrolled3 locationsNCT07350850
Recruiting
Phase 1Phase 2

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma+1 more
Jonsson Comprehensive Cancer Center24 enrolled3 locationsNCT05256641
Recruiting
Phase 2

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 1Phase 2

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more
Medical College of Wisconsin100 enrolled1 locationNCT04186520
Recruiting
Phase 1

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

LymphomaPrimary Central Nervous System Lymphoma
Dana-Farber Cancer Institute15 enrolled2 locationsNCT06475235
Recruiting
Phase 1Phase 2

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 1

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center26 enrolled8 locationsNCT07082868
Recruiting
Phase 2

Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

SintilimabCentral Nervous System LymphomaPirtobrutinib
Zhejiang Cancer Hospital24 enrolled1 locationNCT07416890
Recruiting
Phase 2

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520
Recruiting
Phase 1

Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

Central Nervous System Lymphoma
University of Utah12 enrolled1 locationNCT06607549
Recruiting

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell LymphomaPrimary Central Nervous System Lymphoma (PCNSL)
Ting YANG20 enrolled1 locationNCT07188077
Recruiting

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Hematopoietic and Lymphoid Cell NeoplasmLymphomaLeukemia+3 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT05011045
Recruiting
Phase 1

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
City of Hope Medical Center20 enrolled1 locationNCT06922604
Recruiting

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMultiple Myeloma+6 more
Medical College of Wisconsin500 enrolled1 locationNCT03375619
Recruiting
Phase 1

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

Primary Central Nervous System Lymphoma (PCNSL)
Ono Pharmaceutical Co. Ltd32 enrolled2 locationsNCT07198087
Recruiting
Phase 1

Q702 for the Treatment of Patients With Hematologic Malignancies

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810